Session » Antiphospholipid Syndrome: Clinical Manifestations and New Biomarkers in Antiphospholipid Syndrome

Meeting: 2013 ACR/ARHP Annual Meeting

Abstract Number: 1

Anti-â2GP1- Domain-1 Antibodies Are a Marker Of APS Severity

Abstract Number: 2

Charaterization Of Micrornas Involved In The Regulation Of Atherotrhombosis In Antiphospholipid Syndrome and Systemic Lupus Erythematosus

Abstract Number: 3

The Global Antiphospholipid Syndrome Score (GAPSS) In Primary APS

Abstract Number: 4

Proteomic Analyses Of Monocyte Responses To IgG From Patients With Antiphospholipid Syndrome

Abstract Number: 5

Plasma Levels Of PF-4var/CXCL4L1, A Non Allelic Variant Of Platelet Factor-4 (PF-4/CXCL4), Are Elevated In Patients With Antiphospholipid Syndrome (APS)

Abstract Number: 6

Researchers’ Own Experience In Managing Obstetric Complications In Pregnant Women With Antiphospholipid Syndrome

Abstract Number: 7

Prospective Validation Of The Global Antiphospholipid Syndrome Score (GAPSS)

Abstract Number: 8

Clinical Evaluation Of Two Anti-Beta₂glycoprotein I Domain 1 Autoantibody Assays To Aid In The Diagnosis and Risk Assessment Of The Antiphospholipid Syndrome

Abstract Number: 9

Domain 1 Is The Main Specificity Of Anti-β₂glycoprotein I Antibodies In Systemic Autoimmune Diseases

Abstract Number: 10

Autoantibodies Targeting Domain 1 Of Beta 2 Glycoprotein I As Promising Marker In The Diagnosis and Risk Stratification Of The Antiphospholipid Syndrome

Abstract Number: 11

Catastrophic Antiphospholipid Syndrome (CAPS): Clinical, Immunologic Features, and Outcome Of 441 Patients From The “CAPS Registry”

Abstract Number: 12

Phosphatidiyserine-Prothrombin Complex (aPS/PT) IgG Antibodies Correlate With Lupus Anticoagulant and Specific Pregnancy Complications In Patients With Antiphospholipid Syndrome

Abstract Number: 13

A MORE Specific Immunoassay For The Diagnosis Of APS

Abstract Number: 14

Isotype Dependent Performance Of Beta₂glycoprotein I Immunoassays In Two Diverse Patient Cohorts: Implications For Assay Harmonization and Standardization

Abstract Number: 15

Establishment Of Standardized International Units For IgM ANTI-β₂glycoprotein Antibody Measurement

Abstract Number: 16

Only IgG and IgA β₂glycoprotein I Antibody Isotypes Are Associated With Venous Thrombosis In Systemic Lupus Erythematosus

Abstract Number: 17

Autoantibodies Against Component Of Complement One Contribute To The Complement Activation and Clinical Manifestation Of Antiphospholipid Syndrome (APS) Especially In Refractory Cases

Abstract Number: 18

Clinical Correlates Of Positive Anti-Cardiolipin and β-2 Glycoprotein 1 Antibodies In a Cohort Of 110 Patients At Mayo Clinic

Abstract Number: 19

Association Of Antiphospholipid Antibodied Detected In The Aphl ELISA With Clinical Manifestations Of The Antiphospholipid Syndrome In Two Lupus Cohorts

Abstract Number: 20

Complement Deposition On Platelets Is Associated To Venous Thrombosis In Systemic Lupus Erythematosus

Abstract Number: 21

Factor Xa Reactive Antibodies In Patients With Systemic LUPUS Erythematosus and Antiphospholipid Syndrome Have Differential Effects Upon Coagulation Assays and Endothelial CELLS

Abstract Number: 22

WHAT Is The Prevalence Of NON CRITERIA ANTIPHOSPHOLIPID ANTIBODIES IN Patients With Antiphospholipid Syndrome?

Abstract Number: 23

Seizures In Systemic Lupus Erythematosus Are Not An Inflammatory Manifestation Of Lupus Anticoagulant

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.